Iterum Therapeutics Plc (NASDAQ:ITRM) price on Thursday, March 28, fall -3.14% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.54.
A look at the stock’s price movement, the close in the last trading session was $1.59. The beta value (5-Year monthly) was 2.35. Turning to its 52-week performance, $2.50 and $0.62 were the 52-week high and 52-week low respectively. Overall, ITRM moved 20.31% over the past month.
Iterum Therapeutics Plc’s market cap currently stands at around $20.67 million, with investors looking forward to this quarter’s earnings report slated for May 10, 2024 – May 14, 2024. Analysts project the company’s earnings per share (EPS) to be -$0.93, which has seen fiscal year 2023 EPS growth forecast to increase to -$2.95 and about -$3 for fiscal year 2024.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that ITRM is a Hold. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
ITRM’s current price about 2.48% and -0.93% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.48, while 7-day volatility ratio is 6.71% and 7.41% in the 30-day chart. Further, Iterum Therapeutics Plc (ITRM) has a beta value of 2.36, and an average true range (ATR) of 0.12.
If we refocus on Iterum Therapeutics Plc (NASDAQ:ITRM), historical trading data shows that trading volumes averaged 0.15 million over the past 10 days and 604.49K over the past 3 months. The company’s latest data on shares outstanding shows there are 13.42 million shares.
The 2.52% of Iterum Therapeutics Plc’s shares are in the hands of company insiders while institutional holders own 8.49% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.21 million on Mar 15, 2024, giving us a short ratio of 5.63. The data shows that as of Mar 15, 2024 short interest in Iterum Therapeutics Plc (ITRM) stood at 8.99% of shares outstanding, with shares short rising to 1.17 million registered in Feb 15, 2024. Current price change has pushed the stock -21.83% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ITRM stock continues to rise going into the next quarter.
